Calidi Biotherapeutics, Inc.
CLDI- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855485
No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q2 2026, worth $89.3K in total; no superinvestor holds it.
Other share classesCLDWW
13F holders, Q4 2021
Institutional positions in Calidi Biotherapeutics, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- +27 vs. Q3 2021
- Shares held
- 16.8M
- +16.8M vs. Q3 2021
- Total value
- $164.7M
- +$164.7M vs. Q3 2021
- New holders
- 27
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CLDI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 23 | $89.3K |
| Q1 2026 | 28 | $478.8K |
| Q4 2025 | 27 | $524.7K |
| Q3 2025 | 22 | $353.6K |
| Q2 2025 | 35 | $655.8K |
| Q1 2025 | 36 | $3.09M |
| Q4 2024 | 33 | $1.27M |
| Q3 2024 | 20 | $363.4K |
| Q2 2024 | 32 | $523.2K |
| Q1 2024 | 31 | $1.53M |
| Q4 2023 | 25 | $2.83M |
| Q3 2023 | 13 | $3.54M |
| Q2 2023 | 25 | $39.0M |
| Q1 2023 | 27 | $40.6M |
| Q4 2022 | 25 | $39.6M |
| Q3 2022 | 21 | $36.1M |
| Q2 2022 | 42 | $205.5M |
| Q1 2022 | 40 | $202.4M |
| Q4 2021 | 27 | $164.7M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Calidi Biotherapeutics, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Dark Forest Capital Management LP | 1,357 | $13.0K | 0.00% | +1,357 | New |
| UBS Group AG | 7,415 | $73.0K | 0.00% | +7,415 | New |
| Kohlberg Kravis Roberts & Co. L.P. | 26,523 | $260.0K | 0.00% | +26,523 | New |
| CNH Partners LLC | 41,992 | $412.0K | 0.01% | +41,992 | New |
| Linden Advisors LP | 50,000 | $492.0K | 0.00% | +50,000 | New |
| Segantii Capital Management Ltd | 50,000 | $492.0K | 0.02% | +50,000 | New |
| Pinz Capital Management, LP | 57,000 | $559.0K | 0.22% | +57,000 | New |
| Goldman Sachs Group Inc | 89,967 | $883.0K | 0.00% | +89,967 | New |
| Deutsche Bank AG | 100,000 | $981.0K | 0.00% | +100,000 | New |
| Shaolin Capital Management LLC | 175,000 | $1.72M | 0.04% | +175,000 | New |
| Wolverine Asset Management LLC | 186,905 | $1.83M | 0.02% | +186,905 | New |
| 683 Capital Management, LLC | 200,000 | $1.96M | 0.09% | +200,000 | New |
| Berkley W R Corp | 235,621 | $2.31M | 0.13% | +235,621 | New |
| Oaktree Capital Management LPSuperinvestorOaktree Capital | 300,000 | $2.95M | 0.03% | +300,000 | New |
| Radcliffe Capital Management, L.P. | 400,000 | $3.93M | 0.14% | +400,000 | New |
| Sculptor Capital LP | 500,000 | $4.91M | 0.04% | +500,000 | New |
| Saba Capital Management, L.P. | 621,500 | $6.10M | 0.12% | +621,500 | New |
| Periscope Capital Inc. | 675,900 | $6.64M | 0.18% | +675,900 | New |
| D. E. Shaw & Co., Inc. | 815,816 | $8.02M | 0.01% | +815,816 | New |
| Governors Lane LP | 1,000,000 | $9.82M | 0.71% | +1,000,000 | New |
| Marshall Wace, LLP | 1,062,226 | $10.4M | 0.02% | +1,062,226 | New |
| Beryl Capital Management LLC | 1,159,998 | $11.4M | 0.59% | +1,159,998 | New |
| Driehaus Capital Management LLC | 1,500,000 | $14.7M | 0.15% | +1,500,000 | New |
| Highbridge Capital Management LLC | 1,583,469 | $15.5M | 0.37% | +1,583,469 | New |
| Polar Asset Management Partners Inc. | 1,980,000 | $19.4M | 0.23% | +1,980,000 | New |
| Apollo Management Holdings, L.P. | 1,980,000 | $19.4M | 0.09% | +1,980,000 | New |
| Woodline Partners LP | 1,980,000 | $19.4M | 0.28% | +1,980,000 | New |